These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37350287)

  • 21. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
    Lupi A; Bona RD; Meliga E; Capodanno D; Schaffer A; Bongo AS; Gaudio G; Guasti L; Alexopoulos D; Valgimigli M; Porto I
    Thromb Haemost; 2018 May; 118(5):852-863. PubMed ID: 29618159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
    Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precatheterization Use of P2Y
    Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors.
    Blanchart K; Heudel T; Ardouin P; Lemaitre A; Briet C; Bignon M; Sabatier R; Legallois D; Roule V; Beygui F
    Clin Cardiol; 2021 Aug; 44(8):1080-1088. PubMed ID: 34114653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis.
    Sun J; Xiang Q; Li C; Wang Z; Hu K; Xie Q; Cui Y
    J Cardiovasc Pharmacol; 2017 Apr; 69(4):215-227. PubMed ID: 28045759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
    Godtfredsen SJ; Kragholm KH; Leutscher P; Jørgensen SH; Christensen MK; Butt JH; Gislason G; Køber L; Fosbøl EL; Sessa M; Bhatt DL; Torp-Pedersen C; Pareek M
    Eur Heart J Acute Cardiovasc Care; 2022 Sep; 11(9):697-705. PubMed ID: 35950769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
    Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
    Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.
    Dworeck C; Redfors B; Angerås O; Haraldsson I; Odenstedt J; Ioanes D; Petursson P; Völz S; Persson J; Koul S; Venetsanos D; Ulvenstam A; Hofmann R; Jensen J; Albertsson P; Råmunddal T; Jeppsson A; Erlinge D; Omerovic E
    JAMA Netw Open; 2020 Oct; 3(10):e2018735. PubMed ID: 33001202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials.
    Sethi A; Bajaj A; Bahekar A; Bhuriya R; Singh M; Ahmed A; Khosla S
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):171-81. PubMed ID: 22961908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.
    Yan L; Zhou Y; Yu Z; Xuan M; Xu B; Peng F
    Medicine (Baltimore); 2022 Jul; 101(27):e29824. PubMed ID: 35801776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Koul S; Smith JG; Götberg M; Omerovic E; Alfredsson J; Venetsanos D; Persson J; Jensen J; Lagerqvist B; Redfors B; James S; Erlinge D
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e005528. PubMed ID: 29870381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis.
    Wang Q; Yang K
    Medicine (Baltimore); 2021 Apr; 100(15):e25546. PubMed ID: 33847681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multivessel Versus Culprit-Only Revascularization in STEMI and Multivessel Coronary Artery Disease: Meta-Analysis of Randomized Trials.
    Atti V; Gwon Y; Narayanan MA; Garcia S; Sandoval Y; Brilakis ES; Basir MB; Turagam MK; Khandelwal A; Mena-Hurtado C; Mamas MA; Abbott JD; Bhatt DL; Velagapudi P
    JACC Cardiovasc Interv; 2020 Jul; 13(13):1571-1582. PubMed ID: 32646699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-Analysis Comparing Potent Oral P2Y
    Casula M; Fortuni F; Ferlini M; Fabris F; Oltrona Visconti L; Leonardi S
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):231-240. PubMed ID: 32895853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.